Summary:
Daily administration of filgrastim decreases the duration of severe neutropenia in the clinical setting. A sustained-duration form of filgrastim, pegfilgrastim, significantly reduces scheduling protocols to a single injection per chemotherapy cycle while maintaining therapeutic efficiency. We examined the ability of a single injection of pegfilgrastim to significantly improve neutrophil recovery following autologous bone marrow transplantation (AuBMT) in rhesus macaques. On day 1, postmyeloablation (920 cGy x-irradiation) and AuBMT, animals received either 0.1% autologous serum for 18 consecutive days (n=13), or single doses of pegfilgrastim via the subcutaneous (s.c.) or intravenous (i.v.) route (300 or 100 μg/kg), or a single dose of filgrastim at 300 μg/kg via the s.c. or i.v. route, or filgrastim at 10 μg/kg via the s.c. route (n=4) on a daily basis (range=days 12–17). Pharmacokinetic parameters and neutrophil recovery were assessed. A single dose of pegfilgrastim via the i.v. or s.c. route was as effective as daily filgrastim administration, resulting in significant improvement of neutrophil recovery after myeloablation and ABuMT. Effective pegfilgrastim plasma concentrations were maintained in neutropenic animals until after the onset of hematopoietic recovery. Enhanced pharmacokinetics in AuBMT cohorts are consistent with self-regulating, neutrophil-mediated clearance.
Similar content being viewed by others
References
Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG- CSF): the first 10 years. Blood 1996; 88: 1907–1929.
Morstyn G, Campbell L, Souza LM et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 668–672.
Sheridan WP, Morstyn G, Wolf M et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895.
Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte-colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170.
Bishop MR, Tarantolo SR, Geller RB et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80–85.
Nienhuis AW, Donahue RE, Karlsson S et al. Recombinant human granulocyte–macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest 1987; 80: 573–577.
Monroy RL, Skelly RR, MacVittie TJ et al. The effect of re-combinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood 1987; 70: 1696–1699.
Molineux G, Kinstler O, Briddell B et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724–1734.
Van der Auwera P, Platzer E, Xu ZX et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol 2001; 66: 245–251.
Lord BI, Woolford LB, Molineux G . Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (Peg-r-metHu G-CSF). Clin Cancer Res 2001; 7: 2085–2090.
Viens P, Chabannon C, Pouillart P et al. Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002; 20: 24–36.
Johnston E, Crawford J, Blackwell S et al. Randomized dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522–2528.
Holmes FA, Jones SE, O'Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903–909.
Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35.
Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim one per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731.
Vose JM, Crump M, Lazarus H et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 519.
de Haan G, Ausema A, Wilkens M et al. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000; 110: 638–646.
The Institute of Laboratory Animal Resources, National Research Council: Guide for the Care and Use of Laboratory Animals, Vol. 86. National Institutes of Health: Washington, DC, 1996.
Cheung EN, Cosenza M, Lopez O et al. Modeling of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis in normal animals with mathematical extrapolation to neutropenic settings. Blood 1998; 92 (Suppl. 1): 379.
Roskos LK, Yang B, Schwab G et al. Cytokinetic model of rmethHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the ‘self-regulation’ of SD/01 elimination in non-small cell lung cancer. Blood 1998; 92 (Suppl.): 507A.
Farese AM, Casey DB, Vigneulle RM et al. A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 2001; 19: 514–521.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farese, A., Yang, BB., Roskos, L. et al. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant 32, 399–404 (2003). https://doi.org/10.1038/sj.bmt.1704156
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704156
- Springer Nature Limited
Keywords
This article is cited by
-
The effects of granulocyte colony-stimulating factor on MR images of bone marrow
Skeletal Radiology (2019)